Immunoproliferative Disorders  >>  Torisel (temsirolimus)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

12 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Torisel (temsirolimus) / Pfizer
NCT00086840: CCI-779 in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Terminated
2
60
US
temsirolimus, CCI-779, cell cycle inhibitor 779, Torisel, laboratory biomarker analysis
National Cancer Institute (NCI)
Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia
08/05
 
NCT00033267: CCI-779 in Treating Patients With Mantle Cell Non-Hodgkin's Lymphoma

Completed
2
27
US
temsirolimus, CCI-779, cell cycle inhibitor 779, Torisel
National Cancer Institute (NCI)
Recurrent Mantle Cell Lymphoma
02/06
02/08
NCT00079456: Temsirolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma

Completed
2
25
US
temsirolimus, CCI-779, cell cycle inhibitor 779, Torisel, pharmacological study, pharmacological studies, laboratory biomarker analysis
National Cancer Institute (NCI)
Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
02/07
 
NCT00084916: CCI-779 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Chronic Myelogenous Leukemia in Blastic Phase

Completed
2
74
US
temsirolimus, CCI-779, cell cycle inhibitor 779, Torisel, laboratory biomarker analysis
National Cancer Institute (NCI)
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Blastic Phase Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndromes, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Refractory Anemia With Excess Blasts, Refractory Anemia With Excess Blasts in Transformation, Relapsing Chronic Myelogenous Leukemia, Secondary Myelodysplastic Syndromes
03/07
 
NCT00109967: CCI-779 and Rituximab in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Checkmark P2 data
Mar 2011 - Mar 2011: P2 data
Completed
2
71
US
rituximab, IDEC-C2B8, IDEC-C2B8 monoclonal antibody, Mabthera, MOAB IDEC-C2B8, Rituxan, temsirolimus, CCI-779, cell cycle inhibitor 779, Torisel
National Cancer Institute (NCI)
Recurrent Mantle Cell Lymphoma
09/09
03/12
NCT00290472: CCI-779 in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

Completed
2
89
US
temsirolimus, CCI-779, cell cycle inhibitor 779, Torisel
National Cancer Institute (NCI)
B-cell Chronic Lymphocytic Leukemia, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Malignant Neoplasm, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Splenic Marginal Zone Lymphoma, Waldenström Macroglobulinemia
04/10
04/10
NCT01234974: IGF-1 Inhibitor Pasireotide Lar in Combination With the m-TOR Inhibitor Everolimus

Withdrawn
2
0
US
Pasireotide, Pasireotide s.c., Pasireotide LAR, SOM230, Everolimus, RAD001
Milton S. Hershey Medical Center
Multiple Myeloma
12/12
12/13
NCT00483262: Combination CCI-779 (Temsirolimus) and Bortezomib (Velcade) in Relapsed and/or Relapsed/Refractory Multiple Myeloma

Completed
1/2
63
US
CCI-779, Temsirolimus, Bortezomib, Velcade
Dana-Farber Cancer Institute, Wyeth is now a wholly owned subsidiary of Pfizer, Millennium Pharmaceuticals, Inc.
Multiple Myeloma
01/11
02/12
NCT00787969: Rituximab, Cladribine, and Temsirolimus in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma

Checkmark For initial therapy of mantle cell lymphoma
Jul 2014 - Jul 2014: For initial therapy of mantle cell lymphoma
Completed
1/2
74
US
rituximab, cladribine, temsirolimus, Filgrastim, Pegfilgrastim
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Lymphoma
04/12
06/17
NCT01170052 / 2009-014844-13: Bendamustine and Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Non-Hodgkin's Lymphoma (NHL)

Withdrawn
1/2
20
Europe
Temsirolimus, Torisel®, Bendamustine
Charite University, Berlin, Germany, Wyeth is now a wholly owned subsidiary of Pfizer, Mundipharma K.K.
Mantle Cell Lymphoma
04/12
04/14
NCT01389427: Escalating Doses of Torisel in Combination With Three Chemotherapies Regimens: R-CHOP, R-FC or R-DHA for Patients With Relapsed/Refractory Mantle Cell Lymphoma (MCL).

Completed
1/2
41
Europe
Torisel dose 15 mg and R-CHOP, Arm A cohort -1, Torisel dose 15 mg and R-FC, Arm B cohort -1, Torisel dose 15 mg and R-DHA, Arm C cohort -1, Torisel dose 25 mg and R-CHOP, Arm A cohort 1, Torisel dose 50 mg and R-CHOP, Arm A cohort 2, Torisel dose 75 mg and R-CHOP, Arm A cohort 3, Torisel dose 25 mg and R-FC, Arm B cohort 1, Torisel dose 50 mg and R-FC, Arm B cohort 2, Torisel dose 75 mg and R-FC, Arm B cohort 3, Torisel dose 25 mg and R-DHA, Arm C cohort 1, Torisel dose 50 mg and R-DHA, Arm C cohort 2, Torisel 75 mg and R-DHA, Arm C cohort 3
The Lymphoma Academic Research Organisation, French Innovative Leukemia Organisation
Mantle Cell Lymphoma Refractory
05/15
09/15
BERT, NCT01078142 / 2009-013351-30: Temsirolimus, Bendamustine and Rituximab for Relapsed Follicular Lymphoma or Mantle Cell Lymphoma

Checkmark ICML 2013
Jun 2013 - Jun 2013: ICML 2013
Checkmark Interim P1/2 data in FL, MCL
Nov 2011 - Nov 2011: Interim P1/2 data in FL, MCL
Completed
1/2
39
Europe
Temsirolimus, Rituximab, Bendamustin, Mabthera, Rituxan, Torisel, Bendamustin, Ribomustin, Trenda
Georg Hess, MD, Wyeth is now a wholly owned subsidiary of Pfizer, Mundipharma Pte Ltd.
Follicular Lymphoma, Mantle Cell Lymphoma
09/17
09/17

Download Options